Skip to main content

DIMA Biotech

DIMA_Biotech

DIMA Biotechnology Ltd. is a biotech company focusing on preclinical R&D products and services for druggable targets. They plan to complete the preparation of lead antibody molecules for all druggable targets in the next 3-5 years. DIMA Biotech provides multiple pre-prepared lead antibody molecules for each target to help pharmaceutical companies skip the tedious steps of monoclonal antibody platform establishment and lead molecule screening. Therefore,  companies can  have more time to focus on the biological mechanism and developability study of drug targets, thus accelerating the process of new drug R&D.

Over the years, DIMA Biotech has been deeply engaged in developing and optimizing the underlying technology platforms for preclinical research. Currently, they have established two independently developed core technology platforms:

Single/multiple transmembrane protein eukaryotic expression, preparation and purification platforms, apply mammalian cell expression systems, provide ECD or full-length membrane protein products closest to native conformation and functional validation. In addition, DIMA Biotech has developed five major functional full-length transmembrane protein preparation systems, including Membrane Nanoparticle (MNP), Virus-Like Particle (VLP), Exosome (EXO), Detergent and Synthetic Nanodisc. Thousands of drug target protein products are in stock. 
DimAb® High-throughput single B-cell lead antibody molecule discovery platform. DIMA Biotech has completed the preparation and screening of lead antibody molecules against more than 200 drug targets by this platform in just two years. Moreover, they have formed strategic partnerships with several international pharmaceutical enterprises and licensed several drug target molecules. DIMA’s preclinical development strength is widely recognized by the industry. 


www.dimabio.com

The prices are on request! Contact Us by e-mail info@sobekbio.com

Human ADGRE5 full length protein-synthetic nanodisc FLP100117

PICTO_DIMABiotech.jpg


The add to cart button will appear once you select the values above

Specifications

10µg / 50µg / 100µg

Alternative names:

CD97; TM7LN1

Description:

Human ADGRE5 full length protein-synthetic nanodisc

Background:

This gene encodes a member of the EGF-TM7 subfamily of adhesion G protein-coupled receptors, which mediate cell-cell interactions. These proteins are cleaved by self-catalytic proteolysis into a large extracellular subunit and seven-span transmembrane subunit, which associate at the cell surface as a receptor complex. The encoded protein may play a role in cell adhesion as well as leukocyte recruitment, activation and migration, and contains multiple extracellular EGF-like repeats which mediate binding to chondroitin sulfate and the cell surface complement regulatory protein CD55. Expression of this gene may play a role in the progression of several types of cancer. Alternatively spliced transcript variants encoding multiple isoforms with 3 to 5 EGF-like repeats have been observed for this gene. This gene is found in a cluster with other EGF-TM7 genes on the short arm of chromosome 19. [provided by RefSeq, Jun 2011]

Protein families:

Adult stem cells, Druggable Genome, ES Cell Differentiation/IPS, GPCR, Secreted Protein, Transmembrane

Protein pathways:

N/A

Expression host:

HEK293

Target:

ADGRE5

Molecular weight:

The human full length ADGRE5 protein has a MW of 87.1 kDa

Formulation / Reconstitution:

Lyophilized from nanodisc solubilization buffer (20 mM Tris-HCl, 150 mM NaCl, pH 8.0). Normally 5% - 8% trehalose is added as protectants before lyophilization. Please see Certificate of Analysis for specific instructions.

Usage:

Research use only

More info:

Email info@sobekbio.com

Orders:

Email orders@sobekbio.com